PYC Therapeutics Limited (AU:PYC) has released an update.
PYC Therapeutics, a clinical-stage biotech company, has received Orphan Drug Designation from the FDA for its drug candidate, PYC-001, targeted at treating Autosomal Dominant Optic Atrophy (ADOA), a rare, progressive blinding eye disease. This designation will aid the drug’s progression through clinical trials, offering benefits like tax credits, fee exemptions, and potential market exclusivity for seven years post-approval. The company is preparing to commence a phase 1 clinical trial for PYC-001 later in 2024.
For further insights into AU:PYC stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
